

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Vignia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/857,305	10/03/2001	Robert C. Brunham	1038-1153MIS	3368
24223	7590 06/24/2003			
SIM & MCBURNEY			EXAMINER	
330 UNIVERSITY AVENUE 6TH FLOOR			SHAHNAN SHAH, KHATOL S	
TORONTO, O CANADA	ON MSG IR/		ART UNIT	PAPER NUMBER
			1645	0/
			DATE MAILED: 06/24/2003	8

Please find below and/or attached an Office communication concerning this application or proceeding.

Application No.09/857,305

Examiner: Khatol Shahnan-Shah Art Unit 1645

# NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CAR §1.821 - §1.825 for the following reasons(s):

1. This application clearly fails to comply with the requirements of 37 CAR §1.821 - §1.825. Applicant's M) attention is directed to these regulations, published at 1114 OG 29, May 15, 1990, and at 55 FR 18230, May 1, 1990. 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence M Listing" as required by 37 CAR §1.821(c). 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 XI. CAR §1.821(e). [] 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CAR §1.822 and/or §1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing". 5. The computer readable form that has been filed with this application has been found to be damaged [] and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CAR §1.825(d). 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the []"Sequence Listing" as required by 37 CAR §1.821(e).

### **APPLICANT MUST PROVIDE:**

V

[]

An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".

7. Other:

K

An initial or substitute paper copy of the "Sequence Listing", as were as an amendment directing its entry into the specification.

**Y** 

A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CAR §1.821(e) or §1.821(f) or §1.821(g) or §1.825(b) or §1.825(d).

#### FOR QUESTIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE CONTACT:

For Rules Interpretation, call (703) 308-4216 For CRF Submission help, call (703)308-4212 For Patentin Software help, call (703) 557-0400 Technical Assistance, call (703) 287-0200

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE.

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, DC 20231
www.usofo.gov

APPLICATION NO./ CONTROL NO. 09/857305 FILING DATE 10/3/2001 FIRST NAMED INVENTOR /
PATENT IN REEXAMINATION

ATTORNEY DOCKET NO.

**EXAMINER** 

Khatol Shahnan-Shah

ART UNIT PAPER

1645

8

**DATE MAILED: 6/18/2003** 

Please find below and/or attached an Office communication concerning this application or proceeding.

#### **Commissioner of Patents**

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

APPLICANT IS GIVEN ONE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.F.R.. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Khatol Shahnan-Shah, Art Unit 1645 whose telephone number is (703) 308-8896. If unable to reach examiner, Lynette F. Smith, SPE, can be contacted at (703) 308-3909.

Any questions regarding compliance with the sequence rules requirements specifically should be directed to the departments listed at the bottom of the Notice To Comply.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Khatol Shahnan-Shah, BS., Pharm, MS. Biotechnology Patent Examiner

Art Unit 1645

RODNEY P SWARTZ, PH.D PRIMARY EXAMINER